TRANSCODE THERAPEUTICS, INC.

Our Mission

TransCode Therapeutics is dedicated to the discovery, development, and delivery of RNA interference (RNAi) therapeutics by overcoming the modality’s greatest challenge – the safe and precise delivery of engineered oligonucleotides to cancer-causing genes to induce regressions without recurrence in patients living with cancer.

Transforming cancer treatment

TransCode Therapeutics, an emerging leader in the development of RNAi oncology therapeutics, was created to realize our belief that cancer can be defeated. Our belief is based on a new approach to address what has been the most intractable challenge in RNA therapeutics: delivering an oligonucleotide to its target before the body’s immune system can attack and dismantle it. Because the TransCode platform is not tumor-specific, it has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, as well as glioblastomas.

At TransCode, we are driven by an urgent need to change how cancer is treated both as a therapeutic modality and in terms of improving patient outcomes. We believe in the ability of RNAi therapeutics to offer patients complete regression of their disease without recurrence rather than the current norm of giving patients additional months of survival. Our expectations are matched by our science, which is ambitious but data-driven, revolutionary but realistic, and is fueled by a passion to find a new way to combat and defeat cancer.

‘The Box’ Composed by Salmon Laurent David Cohen & Fradji Marshall - Courtesy of APM Music

Our management and advisory team combines decades of oncology drug discovery and development expertise, life science business acumen and Wall Street knowledge to add both scientific insight and valuable strategic perspective to address our market.

MANAGEMENT TEAM

Click on each image below to view their bio: